In addition, knockout of OTUD6B lead to a significantly enhancement of the anti‐myeloma activity of bortezomib and carfilzomib when using sub‐lethal doses of the drugs (Fig 6G and H). This evidence concerns the gene OTUD6B and plasma cell myeloma.